What they're not telling you: # HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook Hims & Hers stock cratered 15% in premarket trading after the telehealth giant reported a Q1 loss of 40 cents per share—swinging from a 20-cent profit a year prior—as revenue missed estimates while the company restructured its entire GLP-1 drug strategy. The company posted $608.1 million-winklevoss-investment.html" title="Gemini Space Station Soars On $100 Million Winklevoss Investment" style="color:#1a1a1a;text-decoration:underline;text-decoration-style:dotted;font-weight:500;">million in first-quarter revenue against a Bloomberg consensus estimate of $617.5 million, a miss that disguises a more fundamental business model crisis. Hims recorded $33.5 million in restructuring charges including inventory write-downs and transition costs as it abandoned its previous strategy of selling generic copycat GLP-1 drugs.
# THE TAKE: HIMS' GLP-1 Gamble Exposes Telehealth's Fragile Model Wall Street punished HIMS for doing exactly what it should: abandoning the compounding arbitrage that built its empire. The company made billions by flooding the market with cheap semaglutide knockoffs while name-brand makers looked away. That free lunch is ending. The pivot to branded Ozempic and Wegovy signals the unsexy truth: telehealth margins collapse without regulatory gray zones. HIMS can't compete on pure distribution anymore. Amazon, CVS, and Costco are already there. The stock sale reveals investor expectations divorced from reality. They wanted infinite unit economics from a commodity play. Instead, they're getting a pharmacy with worse inventory advantages than Walgreens. This isn't a setback. It's the market finally pricing in that HIMS was always a middleman in a shrinking margin trap. The correction was overdue.
What the Documents Show
The pivot reflects a hard reality the mainstream business press has largely glossed over: the company's proprietary weight-loss formulations couldn't compete on price or perception with branded alternatives from Novo Nordisk and Eli Lilly. Rather than acknowledge this competitive failure directly, CEO Andrew Dudum characterized the transition as "incredibly valuable" and highlighted "near-record levels" of weight-loss adoption following recent marketing campaigns. The financial deterioration runs deeper than the headline miss. Adjusted EBITDA collapsed 51% year-over-year to $44.3 million against an estimate of $46.1 million. Gross margin contracted sharply to 65% from 73% a year earlier, while operating expenses surged 27% to $475.1 million—well above the $446.2 million estimate.
Follow the Money
These aren't the numbers of a company smoothly transitioning strategy; they're the numbers of a company in damage control. The market has noticed: HIMS is down 10% for the year despite aggressive marketing around weight-loss drugs, suggesting investors see structural margin compression ahead. Hims' forward guidance only reinforces this concern. While the company raised full-year revenue guidance to $2.8-$3.0 billion, it slashed adjusted EBITDA guidance to $275-$350 million from a prior outlook of $300-$375 million. For Q2 specifically, the company is guiding to adjusted EBITDA of just $35-$55 million against Wall Street's estimate of $70.1 million—a staggering 50% miss. This telegraphs that near-term profitability will remain under pressure as Hims absorbs the cost of inventory transitions and invests heavily in branded drug acquisition and marketing.
What Else We Know
The broader implication for consumers is worth examining: telehealth companies like Hims built their initial value proposition on disrupting traditional healthcare distribution through lower-cost generic alternatives and direct-to-consumer convenience. By pivoting to selling expensive branded drugs from pharmaceutical giants, Hims is essentially abandoning its disruptive roots and becoming a distribution arm for legacy pharma. Patients seeking affordable weight-loss medications may find that switching to Hims now means paying premium prices for the same branded drugs they could theoretically access through traditional channels—minus the disruption benefit that justified the model in the first place.
Primary Sources
- Source: ZeroHedge
- Category: Money & Markets
- Cross-reference independently — don't take our word for it.
Disclosure: NewsAnarchist aggregates from public records, API feeds (Federal Register, CourtListener, MuckRock, Hacker News), and independent media. AI-assisted synthesis. Always verify primary sources linked above.